| Drug Discovery and Production - Combination drug therapy beats solo treatment for aggressive prostate cancer relapse |
|
|
|
|
| |
|
| |
The latest drug discovery news from News Medical |
|
|
|
 | | |
 Harness Luminescence Power for Accelerated Drug Discovery
Empower your laboratory with a new class of luminometers - Luminescence 96. Its ultra-compact size and intuitive software ensure effortless integration into your drug discovery pipeline, maximizing output with unparalleled precision.
Leveraging its highly sensitive 96 silicon photomultipliers, it offers a linear dynamic range of up to 8 decades and crosstalk elimination. This makes it a versatile tool for a spectrum of luminescence assays, from reporter gene to cell viability assays.
| |
|
|
|
|
|
 | | |  Critical Path Institute's (C-Path) Translational Therapeutics Accelerator (TRxA) today announced its 2024 global Request for Proposals for its Breakthrough Research and Innovation in Drug Development Grants, also known as BRIDGe. | | | | |  A groundbreaking 3D, three-layer nanomatrix vascular sheet that possesses multiple features of atherosclerosis has been applied for developing a high-throughput functional assay of drug candidates to treat this disease, University of Alabama at Birmingham researchers report in the journal Biomaterials. | | | | |  Researchers at The University of Texas at El Paso have identified a novel pharmaceutical compound that successfully kills leukemia and lymphoma cancer cells, potentially paving the way for new forms of therapy. | | | | |  As part of its pioneering approach to drug discovery, the Canadian nonprofit Conscience announced today that its first open science competition has resulted in the identification of seven promising molecules, or "hits," that show potential for new, more effective drugs for familial Parkinson's disease. | | | | |  Vanderbilt University Medical Center received a $13 million Department of Defense grant to lead a multisite clinical trial that will evaluate repurposed FDA-approved drugs as treatment options for patients with Rett syndrome. | |
|
|
|
| | | How would you rate today's newsletter?
| |
|
|
|
|
|
